According to Steven P. Treon, MD, PhD, mutations in MYD88 and CXCR4 can effectively be used to tailor treatment for patients with Waldenström’s macroglobulinemia (WM).
“Linking biological data to clinical data is beginning to identify clinically distinct subgroups… Continue reading
Article from the New England Journal of Medicine
Many of you have had questions about the pathway that led to the FDA approval of Imbruvica for WM. I wanted to share with you the attached video of Dr Treon’s interview on this historic approval which I hope… Continue reading
Featuring information on:
Attached please find our March 2014 published manuscript: “Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance“.
The high prevalence of MYD88 L265P in lymphoplasmacytic cells from bone… Continue reading
” The genomic landscape of Waldenstrom’s Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphoma genesis.: